Regulatory, Quality & Compliance

The voice of the UK pharmaceutical industry since 1891, ABPI (Association of the British Pharmaceutical Industry) represents companies that research, develop and manufacture medicines for patients and the NHS. Its membership spans the full breadth of the sector, from global research-based manufacturers to smaller innovative biotechnology firms, collectively accounting for a significant share of the UK's life sciences economy. The association works at the intersection of industry, government, and healthcare, engaging with the NHS, the Medicines and Healthcare products Regulatory Agency (MHRA), and policymakers across Westminster and the devolved nations. A central part of this role involves shaping the environment for medicines access and pricing , including the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), which governs how the NHS manages its branded medicines bill. Beyond policy, the ABPI publishes widely referenced industry data, workforce reports, and clinical pipeline analyses that serve as standard references across the sector. It also sets the ABPI Code of Practice , the self-regulatory framework governing how member companies promote medicines to healthcare professionals in the UK, administered independently by the Prescription Medicines Code of Practice Authority (PMCPA). The organisation plays a coordinating role in advancing the UK's broader life sciences ambitions, contributing to government strategies around clinical trials, R&D investment, and supply chain resilience. Its annual Figures report is a benchmark publication for understanding the scale and direction of pharmaceutical activity in Britain. Further information is available at abpi.org.uk.

ABX-CRO operates as an independent full-service contract research organisation with a declared specialism in neuroscience, oncology and molecular imaging, applying a translational medicine approach to take compounds from early bench research through to clinical bedside application. The organisation's formal name, ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH, reflects its German origins, and its footprint has expanded internationally through both organic growth and strategic acquisitions. The service portfolio spans the full drug development continuum. On the clinical side, ABX-CRO provides radiopharmaceutical clinical trials , clinical operations, medical monitoring, pharmacovigilance, data management and biostatistics. Complementing these, the organisation offers imaging and dosimetry services alongside regulatory affairs support, preclinical and pharmacy capabilities, and project design and strategy consultancy. Medical device studies are also within scope. Several milestones mark the company's recent expansion. ABX-CRO acquired ClinSmart LLC, a Pennsylvania-based clinical quality CRO described as well-established, extending its North American presence. In India, the company secured official registration and accreditation with CDSCO as a radiopharmaceutical CRO , enabling it to conduct radiopharmaceutical clinical trials in that market. Recognition from the scientific community has also followed: ABX-CRO and Isotope Technologies Munich jointly received the Marie Curie Award from the European Association of Nuclear Medicine (EANM), acknowledging their collaborative work in the nuclear medicine field. The organisation additionally maintains an India office and a jobs programme, indicating sustained operational investment across multiple geographies. Further information is available at abx-cro.com.

With more than two decades of experience accelerating clinical development for emerging biotech companies, Accelsiors operates as a full-service global Contract Research Organisation (CRO) built specifically around the needs of smaller, agile biopharma developers. The company positions itself as a strategic partner rather than a transactional vendor, offering smart, tailored solutions across the full development continuum. Accelsiors delivers an extensive range of clinical trial services covering early-stage and late-stage development. Early-stage capabilities include project management, central and risk-based monitoring, regulatory monitoring and site management, data management, record management, safety management and pharmacovigilance, quality assurance, biostatistics, medical writing, and clinical pharmacology including modelling and simulation. Late-phase services extend to real-world evidence trials, with dedicated consultancy arms covering regulatory, medical and pharmacovigilance, legal and GDPR, and drug development consultancy. A functional service provider (FSP) model is also available for clients seeking embedded expertise rather than full outsourcing. The company serves a broad span of therapeutic areas , including oncology, autoimmune disorders, infectious diseases, endocrinology, respiratory, hepatology and gastrointestinal, nervous system, nephrology, women's health, nephrology, biosimilars, generics, paediatrics, cell and gene therapy, vaccines, orphan disorders, and microbiome research. This breadth reflects the company's positioning as a single-partner solution for biotech pipelines spanning multiple indications. Accelsiors has developed a suite of proprietary methodologies and platforms, among them Hexa-Helix, Quality Drive, StrongCORE Scientific, AcceleROUTE, WideSCOPE Intelligence, ProPATIENT Solutions, and AcceShield, each designed to support specific functions within the clinical development workflow. Further information is available at accelsiors.com.

Rooted in the North American pharmaceutical market since 1968, ACIC has built its reputation on guiding active pharmaceutical ingredients from early sourcing through to commercial production. The company was established by Luciano Calenti, who arrived in Canada to help create one of the country's first synthetic antibiotic manufacturing facilities, with an initial focus on antibiotics such as amoxicillin. ACIC subsequently developed exclusive partnerships with European manufacturers to supply and distribute APIs , ensuring adherence to both FDA and Health Canada regulatory requirements from the outset. Over the decades, the company expanded its technical capabilities significantly. ACIC opened its first R&D laboratory dedicated to chemical synthesis and later constructed a synthesis plant in Brantford, Canada, supporting both research and commercial-scale production. That facility received approval from the US FDA and Health Canada's Therapeutic Products Directorate, reflecting the dual-market compliance that has characterised ACIC's approach throughout its history. The company's work has spanned APIs, injectables, and the development of joint venture manufacturing facilities across North America. Today ACIC positions itself as an integrator of pharmaceutical equipment solutions alongside its pharmaceutical services, operating under the guiding principle of taking products from molecule to market through innovation. This combination of long-standing regulatory experience, synthesis infrastructure, and strategic manufacturer partnerships places ACIC within the broader contract and specialist services segment of the North American pharmaceutical industry. Further information is available at acic.com.

Rather than operating as a single centralised CRO, ACROSS Global Alliance is built on an alliance model that connects experienced local partners across more than 90 countries into a unified clinical trial delivery network. This structure allows sponsors to access genuine in-market expertise, regulatory knowledge, and cultural understanding at each site, rather than relying on generalist staff deployed from a central office. Clinical Trial Management Across Markets The alliance covers the full trial lifecycle, encompassing study design, site selection, patient recruitment, trial execution, specialised diagnostics , and patient-centric care services. Because each local partner operates within their own established regulatory environment, ACROSS Global is positioned to support complex, multi-country studies with greater agility than traditional CRO models permit. The framework is designed to reduce costs and accelerate timelines without sacrificing quality or compliance standards. Who ACROSS Global Serves Sponsors ranging from large pharmaceutical companies to emerging biotech organisations and academic institutions use the ACROSS Global network to enter new markets or scale existing programmes. The cost-effective structure is particularly relevant for organisations managing defined budgets across geographically dispersed studies, where local knowledge directly affects recruitment speed and site performance. The proprietary technology platform supports coordination across the partner network, providing visibility and consistency throughout each programme. Further information is available at across.global.

Part of the 100% family-owned Tiefenbacher Group, AET provides end-to-end pharmaceutical development and out-licensing solutions spanning more than 80 countries. With over 900 employees and its own laboratories and manufacturing facilities, the group builds efficient supply chains for marketing partners across every major regulated market, removing the full burden of development risk from commercial partners and accelerating their time-to-market. Out-Licensing Model and Core Capabilities AET's business model centres on developing, manufacturing, and registering pharmaceutical products before licensing them to partners worldwide. The portfolio covers value-added generic drug development , innovative medicines, and high-potent compounds, addressing three strategic pillars: better affordability, broader global availability, and genuine therapeutic improvement. From early formulation through regulatory dossier preparation, clinical supply, and multi-market registration, AET manages the entire product life cycle on behalf of its licensing partners. A recognised strength is the organisation's expertise in preparing best-in-class regulatory dossiers that support complex simultaneous launches across multiple jurisdictions. This capability has attracted some of the world's most trusted pharmaceutical brands as long-term partners, underpinned by consistent manufacturing quality and a scalable supply-chain infrastructure that handles both small-molecule and high-potency product categories. The Tiefenbacher Group's integrated model, combining in-house R&D, production, and regulatory affairs under one ownership structure, offers partners a single point of accountability from concept to commercial launch. AET's reach across diverse regulatory environments, from the European Medicines Agency to emerging-market agencies, makes it a capable partner for companies seeking to extend the commercial footprint of established or novel pharmaceutical products. Further information is available at aet.eu.

Trusted by the cell and gene therapy sector since 2006, Akron Biotech supplies the ancillary materials that underpin advanced therapeutic manufacturing. Operating under the Akron Bio brand, the company occupies a specialised position in the biotech supply chain, providing the raw materials and contract services that research teams and commercial manufacturers depend on at every stage of development and scale-up. The product portfolio centres on three core categories: cytokines and growth factors , human plasma derived products, and media and media supplements. These materials are critical inputs for cell expansion, gene vector production, and the broader biomanufacturing workflows associated with advanced therapies. Alongside its catalogue offering, Akron Biotech runs dedicated manufacturing services covering proteins, media and buffers, and transfection and transduction reagents, giving clients a single source for both off-the-shelf supply and custom-manufactured components. Quality assurance is presented as a defining characteristic of the business. The company maintains regulatory support documentation and certificates for its materials, reflecting the compliance requirements of partners working in regulated therapeutic development environments. A knowledge centre comprising published posters, publications, and event resources further supports the scientific community using its products. Partnerships and collaborations form part of the company's stated commercial model, positioning Akron Biotech as an integrated supplier rather than a transactional vendor. Its leadership and newsroom functions suggest an active presence in the cell and gene therapy market rather than a passive catalogue role. Further information is available at akronbiotech.com.

With a consulting network of more than 350 specialists spanning research and development and commercial functions, Alacrita Life Science Consulting provides strategic guidance and hands-on execution to biotech and pharmaceutical companies navigating drug development. The firm serves a broad client base that includes virtual and semi-virtual biotechs, established pharmaceutical companies, investors, technology transfer offices, and animal health companies. Alacrita's product development services span the full programme lifecycle, from opportunity mapping and preclinical strategy through clinical development, regulatory affairs, and CMC consulting. On the commercial side, the firm supports business planning, fundraising, interim chief medical officer engagements, and virtual biotech operations. Technology platform strategy, launch planning, and business development round out a service offering designed to cover the stages where specialist input most often determines programme outcomes. The firm also provides enterprise development services including due diligence, valuations, in-licensing and asset scouting, out-licensing, partnering and deal-making, and academic commercialisation. An investor services practice and expert witness capability further extend the scope available to clients. Alacrita's coverage extends across a wide range of product modalities, including antibodies and ADCs, cell therapies, gene therapies, radiopharmaceuticals, peptides and proteins, small molecules, and microbiome drugs. Disease area expertise encompasses oncology, CNS, immunology, haematology, respiratory, endocrine and metabolic conditions, fibrosis, and digestive and gastrointestinal disease, among others. Further information is available at alacrita.com.

Founded in May 2018 and growing entirely organically to a team of 25 or more, Albion Rye Associates is a multi award-winning life sciences recruitment consultancy headquartered in Redhill, Surrey, with a further office in Philadelphia. The firm describes itself as a market-leading executive search and staffing business, and its 2022 Surrey Employer of the Year award reflects its standing within the regional and sector communities. Specialist Coverage Across Life Sciences The consultancy focuses exclusively on the pharmaceutical, biotech, and consultancy sectors, combining more than 50 years of collective recruitment expertise across its team. Core practice areas include Medical Communications and Marketing , Market Access, HEOR and RWE, Market Research and Strategy Consulting, Quality Assurance and Regulatory Affairs, Biometrics, Clinical Research and Clinical Operations, Medical Writing, Pre-Clinical and Drug Discovery, Business Development, Legal and Compliance, and CDMO/CRO placement. Recruitment Solutions Albion Rye Associates supports both employers and candidates through four principal service models: RPO and Project Hires, Retained Search, Exclusive Contingency, and Freelance and Interim engagements. This breadth allows the firm to address volume hiring campaigns and individual executive appointments with equal rigour. Offices in the UK and United States enable the consultancy to place candidates across international markets. Further information is available at albionryeassociates.com.

Formed to bring the portfolio of its Italian parent directly to North American prescribers, Alfasigma USA is the dedicated US commercial subsidiary of Alfasigma S.p.A., the Bologna-headquartered pharmaceutical group created in 2016 through the merger of Alfa Wassermann and Sigma-Tau. The parent operates in more than 90 countries and employs over 3,000 people globally, with a broad product portfolio spanning gastroenterology , hepatology, metabolism and rare disease. US Commercial and Medical Affairs Operations Alfasigma USA manages the full commercial lifecycle for its prescription medicines in the United States, covering regulatory submissions to the FDA, medical affairs, pharmacovigilance and market access. The subsidiary works directly with physicians, gastroenterologists, specialist prescribers, pharmacists and payer organisations to support appropriate product access and patient support programmes. The gastroenterology and hepatology franchise is a core focus of the US operation, reflecting the parent group's longstanding research heritage in digestive health and liver function. Alfasigma USA operates within the frameworks established by the FDA and applicable federal healthcare regulations, functioning as an accountable commercial and regulatory presence rather than relying on third-party licensing or distribution arrangements. Further information is available at alfasigmausa.com.

With a workforce comprising 100% healthcare professionals, including a 15% physician pool, APCER Life Sciences brings deep clinical and scientific expertise to every stage of the product lifecycle. The company is a specialist pharmacovigilance contract research organisation (CRO) serving pharmaceutical, biotech, and medical device partners across more than 100 markets worldwide. Over nearly two decades, APCER has built an integrated service model that spans the full spectrum of drug safety and regulatory requirements. Core capabilities include ICSR case processing, literature surveillance, aggregate reporting, signal management, and risk management programmes such as REMS. The company also provides QPPV and PSMF support, medical information through an integrated response centre, regulatory affairs, medical writing, and quality assurance, enabling sponsors to consolidate multiple functions under a single, accountable partner. Technology sits at the centre of the APCER model. The firm positions its solutions as fit-for-purpose technology-powered platforms , designed to meet the highest regulatory standards while offering clients scalable and flexible engagement models. This approach supports both small innovators and established organisations navigating complex global regulations. The company operates across North America, the United Kingdom, Europe, and Asia, and counts more than 90 customers within its client base. Its stated focus is on building strategic partnerships grounded in trust, transparency, and a customer-first mindset, with the overarching goal of helping safe and effective therapies reach patients worldwide. Further information is available at apcerls.com.

Regulatory navigation for IVD and companion diagnostics sits at the core of what ARC Regulatory does. The firm operates as a specialist contract research organisation serving pharmaceutical, diagnostics and laboratory clients that require expert guidance through the clinical and compliance demands of in vitro diagnostic and CDx development. The service portfolio spans four principal disciplines. On the regulatory side, the team supports clients in navigating global frameworks applicable to IVD and CDx programmes. Clinical monitoring is delivered with a global presence, with a particular focus on IVD and CDx study designs. Quality services cover QMS auditing, risk management and QMS implementation, while ARC Research Laboratories provides IVD development and validation using advanced technologies. The CRO offering guides sponsors from strategy through to study close-out across every phase of IVD and CDx clinical development. A dedicated IVD Clinical Study Sponsor Delegation service allows clients to initiate and manage IVD studies through a single trusted partner. The firm's proprietary ARC360 platform is positioned to accelerate clinical performance studies, supporting monitoring of central testing laboratories across the full clinical development life-cycle. Sector coverage reflects the firm's cross-disciplinary positioning. Pharmaceutical clients benefit from support in translational biomarker programmes and early clinical trial authorisations, including risk-based monitoring of central testing laboratories. Diagnostics companies receive R&D compliance support and full-service CRO capability for clinical performance studies. Laboratory clients access analytical testing capabilities aligned to their regulatory obligations. Further information is available at arc-regulatory.co.uk.